Forest CEO goes mano-a-mano with Carl Icahn

This time, Carl Icahn may have chosen a biopharma adversary as stubborn as himself. And that's saying something. Forest Laboratories ($FRX) CEO Howard Solomon shows no sign of backing down in his defense of the company's current regime. And he's perfectly willing to fight eye-to-eye with the activist investor. No shying away from a public argument here. Report

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.